Testosterone therapy effects on hemoglobin and iron stores
Testosterone therapy increases hemoglobin primarily by stimulating erythropoiesis, which increases red blood cell mass. [1][2] Testosterone also shifts iron homeostasis toward increased iron availability for hemoglobin synthesis by suppressing hepcidin, a key iron-regulatory hormone. [3][4]
Mechanism for elevated hemoglobin
Testosterone increases erythropoiesis through pathways that include increased effective iron delivery to erythroid precursors. [2][5] Testosterone suppresses hepatic hepcidin expression, which increases iron export via ferroportin and supports iron incorporation into red blood cells. [3][4]
Mechanism for low ferritin
Ferritin decreases when increased erythropoiesis increases iron utilization for hemoglobin synthesis faster than iron is restored to stores. [6] Testosterone-driven hepcidin suppression increases iron flux into the circulating compartment, which can lower serum ferritin as iron stores are consumed for erythropoiesis. [4][6]
Hepcidin suppression as the iron-link between testosterone and erythropoiesis
Hepcidin suppression is associated with increased iron incorporation into red blood cells after testosterone exposure. [4] Human data also support that testosterone suppresses hepcidin and increases markers consistent with increased iron availability for erythropoiesis. [5]
Erythropoietin signaling and hemoglobin set-point
Testosterone-induced erythrocytosis has been linked to increased erythropoietin activity and suppressed hepcidin, supporting coordinated expansion of red blood cell production with adequate iron supply. [2]
Evidence that hepcidin may be a key contributor
Experimental models show testosterone suppresses hepcidin to increase iron availability for erythropoiesis. [4] Additional studies indicate hepcidin suppression contributes to testosterone’s erythropoietic effects, while also suggesting the erythropoietic response may not be entirely dependent on hepcidin suppression in all settings. [7]
Clinical implication for interpreting ferritin during testosterone therapy
Low ferritin during testosterone therapy can reflect increased iron utilization from existing stores triggered by augmented red blood cell production and increased iron flux. [4][6]
Monitoring implications
Ferritin should be interpreted in the context of testosterone-associated erythrocytosis, since hepcidin suppression can transiently increase iron turnover even without intrinsic iron deficiency. [3][6] Testosterone therapy–associated hemoglobin elevation is expected to accompany changes in iron parameters that track with increased erythropoietic demand. [2][5]